were Identified In group A (n=47; 64%) and B (n=6; 11 %). The 53 pelll4 mo•alc po1itive Isolates were predominantly NG-MAST ST1407 (87%) and contained an mti'R promoter A-deletion (98%) andporBib alterations G101K/Al02N. All were asdgned to the same NG-MLVA clu1ter that eompri1ed In total 56 isolates. A correlation wu found between decreased eefotulme susceptibility and ST1407 that was bigbly prevalent among vhiton of the Amsterdam STI clinic. The rapid spread of thiJ strlin, wbich alto has been identified in many other countries, might be facilitated by high-rilk se:s:nal behaviour and should be monitored closely to identify potential treatment failure. Quality-as1nred surveillance of ESC susceptibility on a national and international level and exploration of new drugs and/or atrategie1 for treatment of gonorrhea are cruciaL Nei8seria gono"hoeae is the etiological agent of the sexually transmitted infi:ction (STI) gonorrhea. During the last decades, N. gono"hoeae has effectively developed plasmid mediated and/or chromosomally mediated antibiotic resistance to penicilliDs, tetracyclines, fluoroquinolones, and most other antibiotics used for treatment of gonorrhea (3, 16, 25) . This loss of treatment efficacy led in many counJries to discontinuation of these antibiotics as standard first-line treatment regimens, posing new public health concerns (S,2S,3S).
At. present, in most counJries extended-spectrum 31-20-5555629 . E-mail: avdam@ggd.amBterdam.nl. cephalosporin& (ESCs ), such as cefixime (oral) and ceftriaxone (injectable), are the first-line treatment for gonorrhea (3, 4, 25 (8) . Although parenteral ESCs, such as ceftriaxone and cefotaxime, generally show good clinical efficacy for gonococcal infection, various studies have reported the emergence of N. gono"hoeae strains with decreased susceptibility to these antibiotics (10, 17, 20, 21, 24, 25, 33, 38) . Worryingly, a n:cent report described the first European cue (in Sweden) of verified treatment failure of pharyngeal gonorrhea using ceftriaxone (29) , and the first strain worldwide with highlevel resistance to ceftria.xone has recently been reported from Japan (20, 29) .
CHAPTER4
One important antJbiotic resistance dete.rminant that has been associated with this decreased susceptibility and resistance to ESCs in gonococci is the penA mosaic gene, which encodes a mosaic variant of penicillin binding protein 2 (PBP2), the primary lethal target of P-lactam antibiotics (2, 14) . Polymorphisms in at least three important mosaic PBP2 residues (1312M, V316T, and G545S) and epistasis of the polymorphisms in mosaic PBP2 variants cause a marked decrease in susceptibility to cefixime and ceftriaxone (23, 27) . However, additional polymorphisms in the penA gene, e.g. alterations in A501 in PBP2, are important, and still a lot of knowledge is
lacking. Yet, with exception of the Japanese strain (19) it has been well established that the identified alterations in the penA mosaic gene do not seem to be sufficient to attain very high level of ESC resistance without the contnbution of mtrR, porBJ b, and at least one additional unknown resistance determinant (10, 17, 20, 25, 38 (6) . This sharp increase in prevalence was associated with high-risk sexual behaviour and STI eoinfections, which suggested rapid clonal expansion of an antibiotic resistant N. gonorrhoeae strain, mch as was described in other studies (10, 13, 14, 36) .
In the present study, we investigated the transmission patterns, clonality, and phenotypic as well as genotypic characteristics of N. gonorrlweae isolates, which were classified as intermediate susceptJ.blelresistant, borderline susceptible, and susceptJ.ble to cefotaxime, according to EUCAST criteria. All isolates were obtained from well defined high-risk populations in Amsterdam.
MATERIALS AND METHODS
Stuoly oett!Dg, papulatloD, ud umpllag. pcrfonned oo a Bi.c>-Rad C1000 PCR Syotan (Bio-Rad, USA) at 95°C for 2 miD, followed by 35 amplification cycleo of 30 • at 94"C, 60 • at 60°C, and 60 a at n•c. The PCR products were electropboreoed on a 10% polyamylamide gel (Bio-Rad, USA). WHO stmins K and L were UBed ao a positi"" and negative control, "'spectively. WHO K and L (p<M. D345a allele) ll1:raina bodJ. display decreased moceptibility to llSCa due to a pDJA mooaic allele and a pDJA AS01V mulation, reopectively (28) .
N. gt~~~t~rrlulftt! MI.V A. Amplification of the wriabJo.number of tandem RpOOtaequem;a (VN'I'lb) wao pe:rfmmed on a Bio-Rad C1000 PCR Syotem (Bio-Rad, USA). Five VNTR. loci were amplified in two cliffemtt multiplex PClU as deocribed previously {12). The amplified sample• won> diluted I :20 in wata: and 2 J11 of each diluted samplc was (2) "!QR, imloiqaortilo .._.
• Alboaia, Bulpria, Hlmply, Uknioo. RDmonia, RliRia, llllll Czoch Ropublic. mixed wilh 18 1.11 of a I :450 in Wilier dihrted GeneScon IJZ 500 .m.
standard (Applied Biosystems, USA).
After heat denaturation far 5 min at 95"C the fropmtB were oeparated with an ABI 3130 aulomated ooqumcor uain3 the frogmmt anal)osis module. Sizing and calculation of !he number of repeats of each VNTR were performed with Gen.eMarker software v1.80 (Soi\Geo.etics, USA). N. ''""'"""-mnltlutlpD oeqaeace typlnc (NG-MAST). NO-MAST wu performed 81 previously dcocribed (18, 31) . NG-MAST allele numbcn of porB and thpB, and 1Cql1C11CC types (STs) were auigned 1lling the NG-MAST databue (www.ng-maat.net).
pMA, -11, and ptRBlb {!laB) ooqueacblg. The pmA gene, promoter region and the coding oequence of mlrll, and the full-length porBlb gene were ICqliC1ICed u previously described (17) . DNA of the N. gonorr/loeat: WHO F refercru:e llrllin and oterile, UV-trcated woter were included in all nmo 81 positive and negative control, reopeetively (28) .
Data aaaiylh and ltaliltia. Cluster anal)osis of the MLVA types w= performed in Bionumcric• SollwiR vS.! (Applied Ma1h, Belghnn). Statilllical analyoeo were performed using SPSS vl7.0 1101lw1R (SPSS Jne., USA). Sequence alignments were performed using BioBdit v7.0.9 (h11p://www.mbio.ncsu.edu/bioeditlbioedit.html).
RESULTS
Padent characteristics. Of the included patients, 155 (77%) were MSM, 30 (15%) heterosexual men, and 17 women (8%). The patients were predominantly of (9) 2 (5) 23 (21) 3 (5) I (3) 13 (12) 40 (Ji) 31 (J9) 71 (66) 7 (13) 0 7(J) 2 (4) I (3) 9 (8) 7 (13) 7 (18) 20 (17) 18 (32) 12 (31) 33 (31) 17 (30) 14 (36) 32 (30) resistance to these antibiotics, while the proportions in conU'ol group C were markedly lower ( Table 2) . Using an MlC of 0.016 ~glml as an arbitrary cut-off 68% of the group A and 11% of group B isolates showed decreased susceptibility to cefixime and 76% and 57% showed decreased SUBceptibility to ceftriaxone, respectively. In contrast, 0 and 5% of control group C isolates showed decreased susceptibility to cefixime and ceftriaxone, respectively.
Detecdon of a pDIA mosaic allele in N. go~torrlroHe illolatee. A penA mosaic allele was identified in 53 (26%) of the 202 examined N. gonorrhoeae isolates. The penA mosaic gene was exclusively found in isolates that had decreased susceptibility or resistance to cefotaxime. There was a strong positive correlation between N. gonorrlweae isolates with higher cefotaxime MICs and the presence of a penA mosaic allele (Fig. 1 ) . The frequency of the penA mosaic gene was significantly higher in group A (47n4, 64%) than in both group B (6/54, 11%) and group C (On4) (p<O.OOOl, Chh Also the difference between group Band C was significant (p=0.0119, Chh
Cluter analyJill ofNG-MLVA profiles. To examine (Fig 2a) .
NG-ML VA cluster I contained 56 isolates, including all 53 (95% of the cluster) penA mosaic-containing isolates. The remaining three were non-mosaic N. gono7Thoeae isolates that were susceptible to cefotaxime. In cluster IT (n=39) no penA mosaic isolates were found.
The presence of cluster I, which included all 53 ptmA mosaic positive isolates with an identical penA mosaic allele (PBP2 pattern XXXIV), see below, strongly suggests the circulation of one clonal N. go11o7Thoeae strain. A marked association was observed between NG-MLVA cluster I and decreased susceptibility and/or resistance to cefotaxime (95%). Most isolates in cluster I displayed in vitro resistance to tetracycline (89%) and ciprofloxacin (98%) according to EUCAST breakpoints (v1.3). In total, 118/128 isolates (92%) with decreased susceptibility to cefotaxime were also resistant to tetracycline and ciprofloxacin. WT wr NG-MLVA cluster n may represent another group of clonally related strains, characterized by modestly increased MICs of cefotaxime. The proportion of isolates in the cefotaxime MIC groups A, B, and C in clusters I and IT is illustrated in Figure 2b . Twenty-six (67%) of the isolates in cluster n (n=39) had a cefotaxime MIC of 0.125 j!g/ml. Interestingly, 221128 isolates (17%} with a cefotaxime MIC of::::0.125 j!g/ml could not be assigned to a large cluster.
Cha:racterillties of the patients In NG-MLVA ehisten L The patients whose isolates comprised cluster I did not differ significantly from the total population regarding age, gender, sexual orientation, nationality, or eo-infection status (Table 1 ) . Of the patients in cluster I, 48 were MSM {86%), 5 heterosexual men (9~). and 3 women (5%). The patients in cluster I were predominantly Dutch (71 %) and eo-infections with chlamydia (32%) and mv (30%) were common. These characteristics were similar in cluster n. The only important dift'ereru:e between clusters I and IT was the presence of seven (13%} patients with an Eastern
European nationality who were only identified in cluster I. Of these, three (5%) patients were identified as commercial sex workers: one MSM (bisexual man) and two women. In total, four (7%) commercial sex workers were identified in cluster I while none of the patients in cluster IT were commercial sex workers. N. gonorrhoeu multiantigen sequence typing (NG-MAST) of the isolates in NG-ML V A cluster L On all 56 isolates of cluster I, NG-MAST was performed to confirm the clonality of the N. gonorrhoeae sttain harboring a penA mosaic allele and to identify the NG-MAST sequence type(s) (ST) involved. Among these 56 isolates, 9 different NG-MAST STs were identified, two of which have not been previously descnbed. Forty-six (87%) of the 53 pe11A mosaic positive isolates in cluster I were assigned to STI407 and the remaining seven isolates were further differentiated in 5 other STs (Table 3}. • ( The remaining 3 non-mosaic penA isolates in cluster I had 3 different STs with multiple substitutions in both porB and tbpB, suggesting that these isolates contained more distantly related N. gonorrhoeae genotypes (Table  3) .
~IIA sequences of the ilolates within NG-MLVA clutter L PenA sequencing was performed on all 56 isolatc:3 in NG-ML VA cluster I to confum the ideotified penA mosaic positive gel patterns, determine the clonal relatedness of penA, and to identify the penA mosaic sequence type. Within these 56 isolates, all 53 penA mosaic positive isolates showed an identical penA mosaic sequence (PBP2 pattern XXXIV; GenBank accession no. GU723422). In the remaining 3 non-mosaic penA isolates, the penA sequence pattern IT was identified (Table 3) .
Speclflc mutation• In 111trR and ptJrBlb (peiill) In the isolate1 ofNG-MLVA clutter I. We examined two additional antibiotic resistance determinants that are associated with decreased ESC susceptibility. A specific nucleotide (A) deletion in the promoter region of the mtrR gene that causes over-expression of the MtrCDE effiux pump was observed in all 56 isolates of NG-MLVA cluster I. The remaining 3 non-mosaic isolates in NG-ML V A cluster I contained an additional G45D amino acid substitution in MtrR.
PorBlb amino acid substitutions GlOlK and A102N
were detected in all but one penA mosaic positive isolates suggesting a decreased intake of the ESCs, while only one isolate had a wild type porBlb sequence. One mosaic and one non-mosaic isolate had a wild type porBlb sequence while the other two non-mosaic isolates had amino acid substitutions GlOlK and A102D (Table 3) .
Genotypic characterization of a subset of ilolatel In clutter IL We genotypically characterized a subset of nine penA non-mosaic isolates from cluster 11. Eight of the nine isolates had a cefotaxime MIC ~.125 11g/ml; four of these isolates had a borderline ccfotaxime MIC of 0.125 11g/ml (group B) and four isolates had a cefotaxime MIC of0.19 to 0.25 !J.g/ml (group A) and were considered resistant according to EUCAST (v1.3) resistance breakpoints. The remaining isolate that was included was susceptible to cefotllxime (group C) but had a ccftriaxone MIC of0.023 11glml.
All nine non-mosaic penA isolates contained PBP2 pattern XII and the specific nucleotide (A) deletion in the promoter region of the mtrR gene. Eight of the nine CHAPTER4 isolates (including the group C isolate) containedporBlb alterations G101K/Al02D and were assigned NG-MAST ST225. The remaining group A isolate had porBlb alterations G101K/A102N and was assigned NG-MAST ST5012.
DISCUSSION
Decreased in vitro SUI!ceptibility to extended-spectrum cephalosporins (ESCs ), the last remaining treatment option for gonorrhea, is reported in many parts of the world. Due to the increasing number of reports concerning the loss of clinical treatment efficacy of orally administered ESCs, the parenteral ESC ceftriaxone is often considered to be the preferred first-line treatment for gonorrhea (7 ,25) . However, a recent report described the first strsin displaying high-level resistance to ceftriaxone (most likely related to a treatment failure using eeftriaxone) and complete characterization of this strsin (20) . It is now a fear that gonorrhea may become untreatable during certain circumstances and especially in some settings (20, 25) .
In the Netherlands, cefotaxime was used as first treatment option before 2006 due to non-availability of ceftriaxone in recommended dosages. From 2006 onwards, recommended dosages became available and ceftriaxone was recommended as first-line treatment for gonorrhea infections according to the national clinical guidelines which were issued by the Dutch Dennatological and Venereological Society (8) . However, eefotaxime remained the drug of choice for monitoring ESC susceptibility to obtain comparable resistance data over a period of several years.
In the present study, the systematic monitoring of cefotaxime I!IISCeptibility from 2006 to 2008 allowed the detection of N. gonorrhoeae isolates with decreased I!IISCeptibility to ESCs among visitors of the STI outpatient clinic in Amsterdam (6) . To assess these lower levels of antimicrobial resistance, N. gonorrhoeae isolates were classified according to the EUCAST resistance breakpoint for cefotaxime (MIC >0.125 !lg/ml), rather than using the higher resistance breakpoint issued by the CLSI (MIC >O.S )tg/ml). Including N. gonorrhoeae isolates with borderline MICs of exactly 0.125 )tg/ml enabled us to identify antimicrobial resistance determinants, that would have remained undetected when the EUCAST breakpoint for cefotaxime was strictly applied and thus only isolates with a MIC of >0.125 f.L glml were included. In order to confirm whether cefotaxime is a good marker for susceptibility to extended-spectrum cephalosporins in general, we also recultured the N. gonorrhoeae strains and assessed their sensitivity to cefixime and ceftriaxone. Using an arbitrary breakpoint, we confirmed that decreased susceptibility to these other cephalosporins was frequently found in isolates with decreased susceptibility to eefotaxime, and not in control isolates. (20) . We assume that ST1407 was imported in the Dutch population, although it is difficult to determine the exact time point of introduction. This assumption might be supported by the fact that oral ESCs such as cefiximc were never part of the standard treatment regimen in the Netherlands, whereas ST14Q7 has shown a strong association with decreased susceptibility and/or resistance to oral ESCs (10, 22) . A significant association was observed between the presence of the penA mosaic allele and the decreased susceptibility and/or resistance to cefotaxime. However, when the total number of isolates with decreased susceptibility to ccfotaxime (n= 128) was taken into account, only 41% of these isolates contained the penA mosaic allele. Many of the non-mosaic isolates found in NG-MLVA cluster ll (n=39) had moderately increased MICs for cefotaxime. The decreased I!IISCeptibility to cefotaxime in NG-MLVA cluster I was associated with the penA mosaic allele in synergy with alterations in the mtrR promoter region and porBl b, whereas the isolates in NG-MLVA cluster 11 lacked a penA mosaic allele.
Although it is too early for final conclusions since only a limited number of isolates in cluster 11 was characterized, the data suggested that the moderately increased cefotaxime MICs were caused by the synergistic behavior of sequential alterations in non-mosaic penA alleles, mtrR, porBlb, and possibly unknown antimicrobial resistance determinants. AB recent studies showed that penicillin resistance determinants pi/Q and po11A did not significantly affect susceptibility to ESCs, other unknown alterations are likely involved in the development of decreased susceptibility and resistance to ESC (10, 15, 17, 34, 38) . However, accurate determination of the effect of these individual resistant determinants on cefotaxime susceptibility is hindered by the penA. epistatic mutational effects, synergistic behavior of the identified antimicrobial resistance determinants, and deficient knowledge concerning the unknown resistance fiu:tors involved. Accordingly, the clinical relevance of the moderately increased MICs for cefotaxime is still not clear. Special attention should be given to the clinical identification and treatment of pharyngeal gonorrhea, which is predominantly found among MSM and female sex workers. In the present study only 4.5% of strains originated from the pharynx. Pharyngeal gonorrhea is often asymptomatic and more difficult to treat (19, 35) .
This reduced cure rate facilitates accumulation of genetic alterations and might cause the pharynx to act as a reservoir for gene transfer and recombination.
In conclusion, disturbing reports of ccfixime and ceftriaxone treatment failure in well documented cases of urogenital and pharyngeal gonorrhea, respectively, might be the beginning of an impending threat towards ESC resistance and possibly untreatable gonorrhea in certain circumstances spreading worldwide (21, 25, 29, 30, 37 We hereby state that we did not have any commercial or other asi!Ociation that might pose a conflict of interest regarding the study presented in this paper.
